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Introduction
Over the last 8 years the Psychiatric Genomics Consortium 
(PGC; http://pgc.unc.edu) has fundamentally changed 
the landscape for psychiatric genetics research. This has 
been achieved through unprecedented teamwork, involv-
ing more than 900 investigators from 40 countries, allied 
to rigorous methodology. Significantly, the PGC has an 
open-source approach with the main findings freely avail-
able for unrestricted use (http://pgc.unc.edu/downloads). 
Dozens of groups around the world are using PGC data 
to develop better analytical methods and to perform sec-
ondary analyses on a dataset representing more than 400 
000 human participants.
In 2014, the PGC reported an exceptionally careful and 
systematic analysis of all available published and unpub-
lished schizophrenia (SCZ) data in a multi-stage genome-
wide association study (GWAS) of up to 36 989 cases and 
113 075 controls.1 This landmark study sheds light on the 
genetic architecture of SCZ using approaches that had 
previously been successful for other complex biomedi-
cal disorders. Consequently, advances in genomics that 
are revolutionizing other medical disciplines could and 
should be applied to SCZ and other psychiatric disor-
ders. The study identified that a third of genetic risk for 
SCZ could be attributed to common genetic variation of 
individually small genetic effects. By aggregating these 
small effects it was possible to generate genetic risk scores 
(GRS) that not only have predictive power for risk of ill-
ness, but that also identified overlap with other psychiatric 
disorders. The study provided robust association at 108 
risk loci and evidence that these associations are enriched 
at enhancers active in the brain and in immune tissues. 
Individual genes involved in glutamatergic transmission, 
calcium channels and immune function were implicated, 
providing important new avenues for biological research.
This 2014 Nature article can be seen as the end of the 
beginning. The field now faces at least 3 major challenges. 
First, although common genetic variants make a sub-
stantial contribution to risk, most of illness susceptibil-
ity is unexplained. Some of this difference is attributable 
to rare risk variants ranging from large genomic changes 
(resulting from copy number variation) to single base 
changes.2–4 Large samples will be required to generate 
study power as the contribution of individual mutations 
to risk in the population will be very small even if  there is 
a relatively large impact on risk for an individual.5
Second, even though there is now a list of more than 
100 susceptibility loci, interpreting how the implicated 
genes map to identifiable molecular pathways pertinent 
to disease etiology is challenging.6 However, we can learn 
from other complex disorders where the challenge has not 
proved insurmountable (eg, Type 2 Diabetes).7 Recent 
work by Steve McCarroll’s group suggests grounds 
for optimism despite the additional challenges that are 
posed by clinically defined brain disorders like SCZ. The 
extended MHC region has the strongest association with 
SCZ (P ~ 10–31), but this is the most complicated region 
in the human genome with extremely high gene density 
and linkage disequilibrium. McCarroll and colleagues 
convincingly identify copy number variation in the C4 
gene as one source of the MHC association with SCZ. 
Moreover, C4 mediated synapse elimination in a mouse 
model. This finding is important, because it directly con-
nects a GWAS finding to a specific gene with a direc-
tional hypothesis, and directly leads to a novel hypothesis 
about the etiology of SCZ with immediate translational 
implications.8
Finally, in complex disease genetics most common 
loci are likely to have subtle, regulatory effects with only 
a small fraction predicted to impact protein function. 
Consequently, there is a drive to identify rare, highly 
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penetrant mutations as these may be easier to model in 
cellular and animal systems and will complement ongo-
ing efforts to understand the function of common risk 
variants.
The Third Set of PGC Aims
The task for the PGC and the field is to translate genet-
ics discovery into an understanding of SCZ biology. The 
aims of the 2 prior versions of the PGC were focused on 
developing and proving a robust set of methodological 
approaches.9–11 In the next 5 years, the overarching aim 
of what will be the third set of PGC (PGC3) is to iden-
tify biologically, clinically and therapeutically meaning-
ful information from the growing resource of available 
genetic information. Achieving this will require an ambi-
tious investigation of both common and rare genetic 
variation addressing 6 key questions.
What More Can Be Learned From GWAS in SCZ?
Identified common SCZ risk loci that pass a stringent 
threshold of medical significance explain ~5% of genetic 
risk variance. We know that at least another 25% of sus-
ceptibility is explained by common variants that have not 
yet met this threshold and that this may include contribu-
tion from hundreds or even thousands of small effects. 
As effects become smaller the discovery return from 
increasing sample size will diminish. The plan for PGC3 
is to analyze 100 000 cases. In 2016, we expect to attain 
a total of ~65 000 cases. Based on previous average dis-
covery of 4 associations per 1000 cases would expect to 
double the number of confirmed loci. Unpublished data 
supports this observation (O’Donovan MC, personal 
communication).
As larger imputation panels (eg, from the Haplotype 
Reference Consortium) become available it will be pos-
sible to impute and test much less common genetic 
variants (eg, to a minor allele frequency of 0.1% rather 
than the current 1%) widening the field of investigation. 
Larger sample sizes and a greater contribution from non-
European samples will be important in providing greater 
resolution and narrower intervals of association and help 
to determine which variants are likely to be functionally 
relevant.
This increased yield of common risk variants will, in 
turn, inform analyses by the PGC Network/Pathway 
group to identify functionally or biologically connected 
gene sets in SCZ but also across psychiatric disorders. 
The group has developed a statistically robust approach 
that combines multiple analysis programs (including 
FORGE, INRICH, ALIGATOR, and MAGMA) that 
account for technical challenges such as linkage disequi-
librium and gene size. They have published promising 
results from their provisional cross-disorder analyses of 
the existing data.12 Significant efforts will be made to 
expand GWAS investigation through a central pipeline 
across bipolar disorder (BP), major depressive disorder 
(MDD), anorexia nervosa (AN), autism, attention defi-
cit hyperactivity disorder (ADHD), substance use dis-
orders, obsessive-compulsive disorder (OCD)/Tourette 
syndrome, and post-traumatic stress disorder. This will 
substantially increase study power for cross-disorder 
pathway analysis and will also facilitate the Brainstorm 
Initiative discussed below.
What More Can We Learn From GRS?
GRS are a weighted sum of the number of risk alleles 
in a GWAS and can be used to define a genetic “score” 
for each individual in an independent “target” sam-
ple. Since its original application by the International 
Schizophrenia Consortium, identifying sizable genetic 
correlations between SCZ and bipolar disorder, varia-
tions have emerged to allow better effect estimation.13,14 It 
has been shown that GRS for SCZ predict BP cases with 
or without psychosis and also treatment response in SCZ 
patients.15–17 By following an ongoing study of all 9-year-
old twins born in Sweden since 1992, PGC3 will evaluate 
if  GRS for disorders like SCZ can predict developmental 
trajectories that predate full development of the illness. 
By extension, interactions between genotype (measured 
by GRS) and environmental risk factors will also be 
explored. A second aim will be to predict if  each disor-
der will predict signs, symptoms or comorbid diagnosis 
in other groups (eg, MDD GRS predict mood symptoms 
or disorder in SCZ).
“Brainstorm”: What Can We Learn About the 
Relationships Between Brain Disorders?
Co-morbidity between psychiatric disorders is common 
in clinical practice and epidemiological and clinical cor-
relations have been observed between SCZ and many 
other disorders. GRS and other methods have allowed 
cross disorder analyses confirming that observed rela-
tionships between SCZ-BP, SCZ-MDD, and BP-MDD 
reflect shared genetics rather than exogenous environ-
mental factors.18 Other methods such as multi-phe-
notype Mendelian randomization (MMR)19 and LD 
score regression (LDSR)20 can also be applied to allow 
evaluation of genetic relationships between phenotypes. 
Smaller versions of this aim are published, and a far 
more comprehensive analysis is nearing completion.21,22 
Provisional analysis suggests substantial genetic over-
lap between PGC disorders, but also that other correla-
tions (SCZ-smoking) are driven by non-genetic factors.23 
Understanding these overlaps is essential to improving 
classification across disorders as supported by the NIMH 
RDoC initiative. Through the Brainstorm Initiative 
a more ambitious analysis is proposed to combine 
GWAS meta-analyses of all PGC disorders, neurological 
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diseases and brain-related traits to identify other genetic 
relationships.
Can We Evaluate the Role of Rare Copy Number 
Variants in SCZ?
A number of robustly associated copy number variant 
(CNV) loci have been identified already through merg-
ing of summary data at specific candidate loci across 
datasets held by PGC PI’s (reviewed in Kirov2). The 
PGC has developed a centralized pipeline applying mul-
tiple calling algorithms to raw intensity data followed by 
QC, curation and analysis to allow a more systematic 
genome-wide analysis across the PGC disorders. A CNV 
analysis is nearing completion for the SCZ dataset, pro-
viding genome-wide significance evidence for a number 
of loci, but highlighting the power challenges in identify-
ing rare events. Extending the sample to 100 000 cases 
will certainly increase power. Almost all confirmed risk 
CNVs for SCZ also increase susceptibility to other neu-
rodevelopmental phenotypes (called pleiotropy).24 As 
datasets across other disorders expand, cross-disorder 
comparisons will facilitate a deeper understanding of 
the potential phenotypes associated with each risk locus. 
Gene set analysis shows enrichment of genes from the 
N-methyl-D-aspartate receptor (NMDAR) and neuronal 
activity-regulated cytoskeleton-associated protein (ARC) 
postsynaptic signaling complexes at the small number of 
known SCZ CNV loci and it will be interesting to revisit 
this analysis if  more loci can be identified.25
Can We Perform Well-Powered Studies of Rare 
Sequence Variation?
Rare mutations are a sizable reservoir of genetic varia-
tion, often missed by SNP arrays but particularly action-
able.26 Rare variant discovery is challenging and the SCZ 
data suggest overlap between common and rare variation 
at the same loci.3,4,25 Genome sequencing has suggested 
that current sample sizes are insufficient. The PGC will 
perform target sequencing of 200 genes, based on SCZ 
results, in at least 20 000 subjects. This will focus on top 
hits from the PGC2 GWAS study with an emphasis on 
gene sets implicated by GWAS (eg, voltage-gated calcium 
channel signaling and NMDAR).
What Can We Learn From Densely Affected Pedigrees?
De novo mutations can have large effects on SCZ or 
ASD risk but most risk alleles are inherited. Although it 
is essentially impossible for these alleles to become com-
mon in the population they can segregate over a number 
of generations within a pedigree. Many densely affect 
pedigrees have been identified in SCZ and whole genome 
sequencing (WGS) is potentially powerful in helping to 
identify these mutations where they occur. Until now very 
few of these pedigrees have been assessed with WGS. As 
was the case for GWAS, there is substantial work to be 
done to develop standardized methodology and statis-
tical analytical frameworks, and data sharing to allow 
rapid identification and validation of key findings. The 
PGC3 could provide an important forum for this devel-
opment. Crucially, the PGC represents the efforts of hun-
dreds of clinicians who collectively have performed many 
thousands of family history evaluations. By using this 
remarkable reach it should be possible to systematically 
identify the pedigrees most likely to yield rare variants of 
strong effect. Participation will be open to PGC and non-
PGC clinicians from around the world (further details are 
available from author A.C.). The goal is to sequence from 
at least 100 of these pedigrees with a focus on unusually 
densely affected pedigrees, or large pedigrees where there 
is extensive comorbidity within the family.
Conclusions
These 6 research questions are not independent, and it will 
be the ability to integrate data across these questions that 
will determine the project’s success. Beyond developing 
robust methodological approaches this has been a major 
strength of the PGC approach so far. An expanded list of 
common risk loci, with better understanding of whether 
these contribute to other brain disorders will be highly 
informative for Network/Pathway analysis as would the 
ability to incorporate data from rare variant discovery 
into these analyses. GRS methods will make it possible 
to test how these data may relate to the development and 
trajectory of illness, or to core symptomatology. This can 
frame the hypotheses tested in model systems. Rare vari-
ant analysis is likely to be helpful in defining particularly 
actionable mutations for analysis in model systems.
Other developments in the field will also be important 
for PGC3. More than 90% of the human genome rep-
resents non-coding DNA sequences.27 It has long been 
known that noncoding elements have an important role 
in regulating gene expression but efforts to catalogue this 
variation are relatively recent.28 PGC3 is timely as it coin-
cides with international efforts to develop a better under-
standing of the genetic regulation of the developing and 
adult human brain. The PsychENCODE project aims to 
produce a publicly available multidimensional genomics 
resource using tissue- and cell type-specific samples from 
~1000 well characterized health and disease-affected 
human post-mortem brains.29 This will provide important 
context to efforts to understand the biological relevance 
of mutations or genetic variants detected through PGC3. 
Multiple groups around the world are already working on 
the neurobiology of emerging genomics findings. Success 
for PGC3 will be measured by the evaluation of the bio-
logical significance of common and rare genomic findings 
and their relevance to the etiology, diagnosis or treatment 
of SCZ. If  successful this will help to guide and focus the 
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search for those core molecular etiological mechanisms 
most likely to improve patient care.
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